Study S001703

A Trial to Test for Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9068 and Compared With NN1250 and NN2211 in Healthy Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT00983021
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 24
Start: 2009-09
Primary completion: 2009-12
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Healthy
Interventions: DRUG:insulin degludec/liraglutide; DRUG:insulin degludec; DRUG:liraglutide; DRUG:placebo
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2009-011269-95; OTHER:U1111-1111-8859; NIH:2009

Registered primary outcomes

Number and severity of adverse events, number and severity of local tolerability issues at the injection site, number and severity of hypoglycaemic episodes [assessed 0-96 hours after trial product administration]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0014347	Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapy. Kapitza C, Journal of clinical pharmacology	2015	Randomized trial	PMID 25998481 DOI	registry reference RESULT:25998481